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Introduction and study overview
Retinopathy of prematurity (ROP), is an eye 
disease that mainly affects the most prematurely 
born and sickest babies. ROP is still one of the 
leading causes of childhood blindness worldwide. 
Depending on the level of neonatal care, ROP can 
also occur in more mature babies.1 Since its first 
description in 1942 by Terry et al. [2] but espe-
cially during the last years, the management of 
ROP has changed tremendously [3]. First, in the 
1950s, the causative association between the ris-
ing incidence of ROP and the then usual high oxy-
gen concentrations in incubators was identified 
[4]. This resulted in the preventive measure of 
lowering oxygen concentrations, reducing on the 
one hand the incidence of ROP while increasing 
on the other hand, unfortunately, the death rate 
of preterm born infants [5]. The optimal oxygen 
concentrations to be applied to this vulnerable 
population is even nowadays unknown, although 
several interventional clinical trials as well as me-
ta-analyses on the use of oxygen in preterm born 
infants were conducted in recent years [6-8]. 
The first prospective clinical trial in the field 
of ROP was the CRYO-ROP trial, which investi-
gated if cryocoagulation could reduce the risk 
for developing unfavourable structural outcome 
in eyes with stage 3+ in zone I or II in at least 5 
contiguous or 8 cumulative clock hours (defined 
as threshold disease) [9]. Already the prelimi-
nary 3-months results were very promising and 
showed a reduction of the risk of unfavourable 
outcome from 51.4 % in the natural history group 
to 31.3 % in the intervention group, which result-
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ed in an adaption of the study protocol to treat 
all infants with a bilateral zone I disease with 
cryocoagulation in both eyes (in comparison to a 
unilateral treatment at the beginning of the trial) 
[10]. As the final results in 1990 confirmed the 
preliminary results, cryocoagulation became the 
first treatment for threshold ROP, although the 
outcomes were far from optimal [11]. 
The next big interventional trial was the 
ETROP (Early Treatment for Retinopathy of Pre-
maturity) trial, in which eyes with a “high-risk” 
pre-threshold ROP were either treated mainly by 
laser coagulation at this early stage or managed 
conventionally (wait and see until an ROP re-
gressed or progressed to threshold disease stag-
es) [12]. The results of the ETROP trial (2004) 
support the use of laser treatment for any stage 
of ROP with plus disease in zone I and for zone I 
stage 3 without plus disease as well as for zone II 
stages 2 and 3 with plus disease. These treatment 
criteria from the ETROP trial still form the basis 
for several national treatment guidelines [13, 14]. 
With the BEAT-ROP (Bevacizumab Eliminates 
the Angiogenic Threat of ROP) trial the anti-VEGF 
drug Bevacizumab was first investigated in a pro-
spective randomized controlled trial for zone I or 
posterior zone II stage 3+ ROP in comparison to 
laser coagulation. The study found a significantly 
better outcome after anti-VEGF treatment in eyes 
with zone I disease compared to laser [15]. It is 
important to note that one of the main differenc-
es between anti-VEGF and laser treatment is that 
after anti-VEGF treatment, the physiologic vas-
cularization continues to the periphery whereas 
after laser coagulation, functionless scar tissue 
develops in the treated areas. Potentially anti-
VEGF treatment can thus, in addition to halting 
disease progression reduce the risk of visual field 
loss for these infants. If the physiologic vascular-
ization after anti-VEGF treatment does not reach 
the periphery, however, a significant risk of ROP 
reactivation ensues [15]. Since publication of the 
BEAT-ROP results in 2011, anti-VEGF treatment 
for ROP has become a widely used treatment 
option – despite important unsolved questions 
particularly regarding long-term safety and dos-
ing [16]. Dose finding studies had not been con-
ducted prior to BEAT-ROP and after publication 
of BEAT-ROP, most treatment centers adopted the 
50% adult dose of bevacizumab as it has been 
used in the BEAT-ROP trial. With regard to sys-
temic safety, concern was raised with regard to 
bevacizumab since it suppresses systemic VEGF 
levels for weeks after intravitreal injection – a fact 
that may not be harmful in adult patients but is of 
unknown significance in a developing organism 
where several organs still require growth factors 
for normal growth and development [17].
The CARE-ROP (Comparing Alternative Ra-
nibizumab dosages for safety and efficacy in ROP) 
trial then tried to answer some of these unsolved 
questions by investigating lower anti-VEGF doses 
and with ranibizumab an anti-VEGF compound 
with significantly shorter systemic half-life (and 
thus theoretically less effect on systemic VEGF). 
Both ranibizumab doses used in CARE ROP (24% 
and 40% of the usual adult dose) were found to 
be equally effective in controlling acute ROP and 
did, in contrast to bevacizumab, not alter systemic 
VEGF levels (results published in 2018) [18]. In 
the global RAINBOW (Ranibizumab versus laser 
therapy for the treatment of very low birthweight 
infants with retinopathy of prematurity) trial 
(published in 2019) laser coagulation was inves-
tigated in comparison to two low doses of ranibi-
zumab (0.1 mg and 0.2 mg) confirming that the 0.2 
mg dose ranibizumab is effective in the treatment 
of ROP and additionally showing that it may even 
be more effective than laser coagulation.19 Impor-
tantly, this was found to be the case not only to the 
most central ROP zone (zone I), but also for all of 
zone II disease (both posterior and anterior). An 
important characteristic of the trial design of both 
the CARE-ROP as well as the RAINBOW trial was 
the fact that a re-treatment with the same dose of 
ranibizumab was allowed if reactivation of treat-
ment requiring ROP was noted after an interval of 
at least 4 weeks post initial treatment. Such a treat-
ment approach accounts for the fact that some 
babies might be efficiently treated with one dose 
of ranibizumab and others might need more anti-
VEGF (i.e. a re-injection), thus allowing to titrate 
the appropriate concentration individually per 
child over time. Since September 2019 ranibizum-
ab is approved by the European Medicine Agency 
in the dose of 0.20mg for the treatment of ROP 
zone I stage 1+, 2+, 3+/- as well as zone II stage 3+ 
and aggressive posterior ROP (AP-ROP) [20]. 
The PEDIG (pediatric eye disease investigator 
group) trial investigated how low the dosing of 
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anti-VEGF drugs in ROP treatment can go with-
out losing its effect. The study found in 2017 that 
bevacizumab at 2.5 % of the adult concentration 
(0.031 mg) was still able to effectively treat ROP 
[21]. In several of the lower dose arms, however, 
re-treatments were frequently necessary and it 
needs to be mentioned that bevacizumab needs 
to be diluted for such treatment approaches, add-
ing some difficulties for applying this in clinical 
reality. Bevacizumab at any dose remains an off-
label treatment for ROP. 
At the moment, the FIREFLEYE trial is ongo-
ing, in which aflibercept, another anti-VEGF com-
pound, is compared against laser treatment in a 
global phase III trial [22]. The initial results of 
this trial are awaited for 2021. 
Apart from ROP treatment other initiatives 
are currently underway and have the potential 
to change the way we diagnose and treat ROP. 
For example, a phase II trial investigated if con-
tinuous application of rhIGF-1/rhIGFBP-3 from 
birth to the age of 29 weeks of postmenstrual age 
would reduce the incidence of ROP in babies born 
between 23 and 27 weeks GA [23]. Another trial 
investigated the effect of polyunsaturated fatty 
acids on the risk of ROP [24]. Both these treat-
ment approaches are based on theoretic consid-
erations and results from animal studies and are 
worthwhile pursuing. Other trials are focusing 
on propranolol as preventive treatment for ROP, 
based on promising initial results from pilot trials 
but in need of large-scale validation. Beyond ROP 
treatment and prevention, we will see a new ROP 
nomenclature, ICROP 3, being published in 2021 
taking into account the new forms of the disease 
we see after anti-VEGF therapy (namely regres-
sion and reactivation). We have in recent months 
also seen important progress in diagnosing and 
grading ROP with the help of artificial intelligence 
[25, 26] and we have seen ROP severity scores be-
ing developed to better compare ROP disease se-
verity during the course of an individual disease 
[27, 28]. 
Risk factors for developing ROP  
and preventive measures
Certain parameters around birth and during 
neonatal care increase the risk for ROP [29]. Es-
pecially gestational age and birth weight are two 
well-known factors driving ROP risk [30]. The 
earlier and the less mature a baby is born the 
higher is the risk to develop ROP. High levels and 
fluctuating levels of postnatal oxygen supplemen-
tation [31], long-term parenteral nutrition [32], 
repeated red blood cell transfusions [33], and 
sepsis [33] as well as a generally unstable postna-
tal clinical course are all parameters that increase 
the risk for developing an ROP. 
In order to prevent an infant from developing 
treatment requiring ROP, certain measures can be 
undertaken: For example, antenatal steroids can 
be given to the mother to improve lung matura-
tion before preterm birth [34]. As oxygen is the 
most important modifiable risk factor for devel-
oping ROP but on the other hand necessary for 
the babies to survive without long-term disabili-
ties, careful management of postnatal oxygen in-
cluding training of involved experts, appropriate 
equipment, guidelines and a sufficient number of 
trained personnel is essential [35]. Continuously 
working on the improvement of neonatal care 
including reduction of infection rates and blood 
sampling are additional measures that can be tak-
en. Optimizing postnatal nutrition including the 
introduction of breastmilk as early as possible, 
support of breastfeeding in general, as well as a 
focus on developmental care and skin-to-skin-
contact are also known preventive measures for 
unfavourable postnatal developments including 
ROP [36, 37]. 
ROP-screening criteria
ROP screening criteria are different around 
the world depending on which evidence base (e.g. 
ETROP or the CRYO-ROP trial, or national char-
acteristics of babies who develop ROP requiring 
treatment) is chosen. Depending on the specific 
national guideline, different gestational ages and 
different  birthweight criteria are chosen to de-
fine who qualifies for ROP screening [38]. These 
differences between national screening criteria 
are sensible as they reflect the existing neonatal 
characteristics in the respective countries. 
A treatment requiring ROP that is not treated, 
is sight threatening for the child and negatively 
affects the whole life of these children and their 
families. Therefore, all babies that are at risk 
of developing a sight threatening ROP need to 
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be included in ROP screening measures. On the 
other hand, as few children as possible who do 
not develop the need for ROP treatment should 
be included as the screening procedure is stress-
ful for the child and binds valuable healthcare re-
sources. It is important to define the best possible 
balance between screening every child at risk for 
ROP and avoiding stressful examinations for in-
fants who are not at risk. 
Neonatal care continuously develops and 
thus the characteristics of babies change. There-
fore, existing national guidelines need to be re-
viewed and adapted on a regular basis. The Ger-
man ROP screening guideline, co-developed by 
German paediatric and ophthalmologic societies, 
was recently revised [39]. The updated version 
including the main changes will be presented be-
low. One of the changes was that the upper ges-
tational age limit for ROP screening was lowered 
from ≤ 32 weeks to ≤ 31 weeks gestational age. 
This means that now all infants born ≤ 31 weeks 
are automatically included in the ROP screening 
program independent of additional risk factors. 
Infants between 31 and 32 weeks are no longer 
screened because data from the German Retina.
net ROP Registry found that in Germany these 
infants are not at risk for ROP (as long as no ad-
ditional risk factors exist) [40]. In addition to the 
gestational age criteria, all infants are screened 
who have a birthweight of < 1500 g, require >5 
days postnatal oxygen supply or ECMO treatment 
or who have an otherwise complicated postna-
tal course [40]. With this adaptation the German 
guideline now follows the trend in other Euro-
pean countries as well as the American guideline 
on ROP screening that all have lowered their up-
per ROP screening age over the recent years. An 
overview of the updated German screening indi-
cations is given in Table 1. 
Regarding the timing of the initial and fol-
low-up screening assessments the German ROP 
screening guideline remained unchanged: The 
first screening is regularly undertaken during the 
6th postnatal week, but not before a postmen-
strual age of 31+0 weeks. Follow-up screening 
exams are regularly done on a biweekly basis un-
til either there is a treatment indication or until 
the retina is fully vascularized. The time interval 
can be adapted depending on the retinal findings 
observed and can either be shortened to weekly 
intervals or shorter (for example if ROP in zone 
I or posterior zone II is present or if stage 2 or 
3 without plus disease is observed), or it can be 
expanded to longer intervals of up to three weeks 
(for example if ROP in zone III is observed and no 
signs of ROP are present). Follow-up screening 
exams can be discontinued when the vascular-
ization reaches the ora serrata and the expected 
date of delivery is achieved (and if no treatment 
has occurred – after treatment, follow-up exams 
have to continue longer, see below).  
Treatment of ROP
The updated German guidelines for screen-
ing and treating ROP now advises for most of the 
treatment requiring stages of ROP either anti-
VEGF injection or laser coagulation (see Table 
2) [39]. Only stages 4 and 5 are recommended 
to be treated with retinal surgery instead. One of 
the novelties in the revised treatment indication 
is that in eyes with stage 3+ in zone II treatment 
can be initiated if only one clock hour is affected 
by stage 3 disease. This used to be more conser-
vative in previous versions of the guideline. The 
second novelty is that after ranibizumab became 
approved for ROP treatment in Europe by the 
end of 2019, this treatment modality is now also 
included in the German treatment recommenda-
tion [41].
When a decision between laser photocoagu-
lation and anti-VEGF injection must be made, all 
positive and negative aspects of the two treatment 
options need to be considered: laser photocoagu-
lation carries no risk for an endophthalmitis and 
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Table 1. Indications for ROP screening in Germany [39]
Gestational age 
unknown
All babies with a birthweight  
< 1500 g, independent of oxygen 
supplementation
Gestational age < 31+0 
weeks
All babies, independent of 
oxygen supplementation
Gestational age ≥ 31+0 
weeks and ≤ 37+0 
weeks
Babies with additional risk 
factors like postnatal oxygen 
supplementation > 5 days
ECMO therapy relevant 
concomitant diseases  
(e.g.: severe necrotizing 
enterocolitis, bronchopul-
monary dysplasia, sepsis, 
anaemia requiring transfusion)
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usually does not lead to late reactivations after 
treatment. It does however, turn retinal tissue 
into functionless scar tissue, takes longer time 
under anesthesia to administer treatment and is 
associated with a higher prevalence of high myo-
pia. Anti-VEGF can be done under local anesthe-
sia or with a short analgosedation, leads to faster 
treatment effects (which may be advantageous in 
particularly aggressive cases), does not destroy 
viable retinal tissue and is associated with lower 
rates of high myopia. It does however require lon-
ger follow-up exams at frequent intervals due to 
the risk of late reactivations [42]. Table 2 summa-
rizes the advantages and disadvantages of laser 
photocoagulation as well as anti-VEGF treatment. 
Other treatment options like cryocoagulation 
are no longer recommended except for maybe 
very special cases where both anti-VEGF and la-
ser treatment cannot be applied. 
Table 3 gives an overview over the treatment 
recommendations depending to the different 
treatment indications according to the current 
German guideline [41]. 
Post-operative follow-up
The recommended procedure of post-oper-
ative follow-up visits depends on the treatment 
method. After laser coagulation, weekly assess-
ments should take place until a significant reduc-
tion of ROP activity is seen and it is ensured that 
confluent laser scars cover all avascular retinal ar-
eas. If this is the case, the follow-up intervals can 
be expanded and continued until a stable stage of 
ROP without any active proliferations, retinal trac-
tions or plus disease is achieved. After anti-VEGF 
treatment, the first assessment should take place 
within four days after treatment in order to rule out 
any potential treatment associated complications 
like endophthalmitis. The following visits should 
then be scheduled according to the retinal findings 
and the recommendations for ROP screening be-
fore treatment (see above). Different to both laser 
treated eyes and untreated eyes, follow-up exams 
after anti-VEGF treatment must continue for a lon-
ger time at frequent intervals. Peripheral avascu-
lar areas can lead to late reactivations through the 
expression of VEGF that is no longer inactivated 
by anti-VEGF molecules once these have left the 
eye into the circulation. The timeframe how fast 
Table 2. Comparison of the advantages and 
disadvantages of laser photocoagulation and anti-VEGF 
therapy (adapted from M. Grundel [42])
Laser photocoagulation
Advantages: No intraocular procedure and therefore 
no risk of endophthalmitis
Usually complete photocoagulation of 
avascular areas in one treatment 
Disadvantages: Lengthy procedure, which usually 
requires general anesthesia
High expertise of the treating physician 
required
Longer duration until the therapeutic 
effect is achieved
Irreversible destruction of retinal 
tissue resulting in possible visual field 
restrictions
Anti-VEGF treatment
Advantages: Fast treatment procedure 
Treatment possible without general 
anesthesia
No destruction of retinal tissue, 
physiologic vascularization can continue 
Lower rate of high myopia 
Disadvantages: Intraocular procedure with risk for 
endophthalmitis 
Intraocular drug levels decrease over 
time leading to potential risk of late ROP 
reactivation 
Frequent long-term follow-up 
assessments necessary to detect 
potential late reactivations
Some anti-VEGF agents are known to 
influence the systemic VEGF levels over a 
long period of time
As VEGF inhibitors are relatively new in 
the treatment of ROP only limited long-
term data exists
Table 3. Treatment indications according to the current 





I 1, 2, 3 + Anti-VEGF or laser 
coagulation
I 3 - Anti-VEGF or laser 
coagulation
I/II Aggressive ROP + Anti-VEGF or 
laser coagulation 
(treatment sometimes 
necessary within 24 
hours after diagnosis)
II 3 (new: already 
when only one 
clock hours is 
affected)
+ Anti-VEGF or laser 
coagulation
III 1, 2, 3 +/- Usually no treatment
Stage 4 or 5 Retinal surgery 
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this happens may differ from infant to infant. It is 
important to acknowledge that a reactivation of 
treatment requiring ROP can occur even several 
months after anti-VEGF treatment [43, 44]. The 
literature describes late recurrences of active ROP 
up to 7 months after treatment [43, 45]. In case 
regular follow-up exams cannot be guaranteed, la-
ser photocoagulation of remaining avascular areas 
can be the best option. 
Long-term outcomes after treatment
If not treated timely, an ROP can still today 
be a sight threatening disease. Laser coagula-
tion has been standard of care since the results 
of the ETROP trial were published, which is not 
even 20 years ago [12]. The BEAT-ROP trial pub-
lished their initial results in 2011 [15]. The com-
pounded data on long-term outcomes after treat-
ment of ROP is thus not very large. It is described 
that after laser coagulation the risk for develop-
ing high myopia is considerably higher than after 
anti-VEGF treatment [46]. The risk for a late re-
activation of ROP, in contrast, is higher after anti-
VEGF treatment and may also occur much later 
than after laser coagulation [45]. A retrospec-
tive analysis from Morin et al. reported poorer 
neurodevelopmental outcomes after anti-VEGF 
treatment than after laser coagulation [47]. This 
analysis, however, needs to be interpreted with 
caution as for example in the bevacizumab group 
the percentage of infants with a zone I disease 
was higher than in the laser arm, which might be 
a sign of unequal distribution between the study 
groups. Long-term outcomes from the CARE-ROP 
and the RAINBOW trials are expected in 2021.
Data-collection
Most hospitals where treatment for ROP is 
performed, have relatively low treatment num-
bers per year. While this is a good sign in general, 
it makes data collection and interpretation very 
difficult and prone to bias and error. We have 
therefore in 2012 established the German Retina.
net ROP registry to combine data from as many 
centers as possible and collectively analyze our 
ROP treatment data [16, 48]. Until now data from 
more than 600 treated eyes was entered into the 
database. Many decisions in the updated German 
screening and treatment guidelines were influ-
enced by evidence from this registry data. We are 
currently in the process of expanding this German 
registry into an international database and would 
be very happy to include centers from as many 
countries as possible. Only in a combined effort 
will it be possible to yield strong and reliable data 
for future treatment and guideline decisions (see 
Figure 1 for the logo of the European wide ROP 
registry project EU-ROP that will be launched in 
2021). Centers or individual experts treating ROP 
are very welcome to contact the authors for par-
ticipation in this project.
Fig. 1. The EU-ROP project will be launched in 2021 as a registry 
project to collect and analyze data from treated ROP infants 
across different European countries. All centers treating ROP 
are invited to join this project and contribute their treatment 
data for joint analysis and publication. 
Conclusion
Recommendations for ROP screening and 
treatment have both changed over the recent 
years. New treatment options, like anti-VEGF 
treatment, can be useful alternatives if applied 
carefully and with sufficient long-term follow-up. 
In order to further improve the management of 
ROP, a joint effort to collect real world data on a 
national as well as an international level will be 
necessary. The EU-ROP registry initiative invites 
participants to contribute their ROP treatment 
data to this joint effort. More data can be obtained 
from the website www.eu-rop.org. 
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